| Literature DB >> 19001271 |
Ralph R Weichselbaum1, Hemant Ishwaran, Taewon Yoon, Dimitry S A Nuyten, Samuel W Baker, Nikolai Khodarev, Andy W Su, Arif Y Shaikh, Paul Roach, Bas Kreike, Bernard Roizman, Jonas Bergh, Yudi Pawitan, Marc J van de Vijver, Andy J Minn.
Abstract
Individualization of cancer management requires prognostic markers and therapy-predictive markers. Prognostic markers assess risk of disease progression independent of therapy, whereas therapy-predictive markers identify patients whose disease is sensitive or resistant to treatment. We show that an experimentally derived IFN-related DNA damage resistance signature (IRDS) is associated with resistance to chemotherapy and/or radiation across different cancer cell lines. The IRDS genes STAT1, ISG15, and IFIT1 all mediate experimental resistance. Clinical analyses reveal that IRDS(+) and IRDS(-) states exist among common human cancers. In breast cancer, a seven-gene-pair classifier predicts for efficacy of adjuvant chemotherapy and for local-regional control after radiation. By providing information on treatment sensitivity or resistance, the IRDS improves outcome prediction when combined with standard markers, risk groups, or other genomic classifiers.Entities:
Mesh：
Substances：
Year: 2008 PMID： 19001271 PMCID： PMC2587578 DOI： 10.1073/pnas.0809242105
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205